
A new checkpoint inhibitor targeting PD-L1 is now in a myeloma clinical trial to be tested alone, with pomalidomide, or pomalidomide/dexamethasone. Checkpoint inhibitors take the "brakes" off the immune system so that it can be free to kill the myeloma cells. Durvalumab has already received fast-track approval by the FDA for bladder cancer for single-agent use. Because blood cancers like multiple myeloma are typically treated with combination therapies, durvalumab is being tested both alone and with other traditional myeloma combinations. This trial is for relapsed/refractory multiple myeloma patients and will be open in 13 trial sites in the US. To learn more about how to join this clinical trial, click here: Durvalumab Clinical Trial

about the author
Jennifer Ahlstrom
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of HealthTree Foundation (formerly Myeloma Crowd).
More on Life With Myeloma
Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.
Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.
Thanks to our HealthTree Community for Multiple Myeloma Sponsors:






.svg_7bb6fd32-1b73-4ca9-9a2f-8fd6fc59d528.png?alt=media)